tradingkey.logo

ANI Pharmaceuticals Inc

ANIP
82.850USD
+0.020+0.02%
收盘 12/19, 16:00美东报价延迟15分钟
1.86B总市值
48.51市盈率 TTM

ANI Pharmaceuticals Inc

82.850
+0.020+0.02%

关于 ANI Pharmaceuticals Inc 公司

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.

ANI Pharmaceuticals Inc简介

公司代码ANIP
公司名称ANI Pharmaceuticals Inc
上市日期May 04, 2000
CEOLalwani (Nikhil Suresh)
员工数量897
证券类型Ordinary Share
年结日May 04
公司地址210 Main Street West
城市BAUDETTE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编56623
电话12186343500
网址https://www.anipharmaceuticals.com/
公司代码ANIP
上市日期May 04, 2000
CEOLalwani (Nikhil Suresh)

ANI Pharmaceuticals Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
411.22K
-12.17%
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
310.13K
+8.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
92.59K
+12.47%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
84.02K
-6.53%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
60.19K
-4.31%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
58.41K
-16.62%
Mr. Thomas Andrew (Thom) Rowland
Mr. Thomas Andrew (Thom) Rowland
Senior Vice President, Head of Established Brands
Senior Vice President, Head of Established Brands
40.04K
-11.05%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
36.52K
-34.62%
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
25.16K
-6.68%
Mr. Matthew J. (Matt) Leonard
Mr. Matthew J. (Matt) Leonard
Independent Director
Independent Director
6.86K
-57.96%
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
411.22K
-12.17%
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
310.13K
+8.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
92.59K
+12.47%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
84.02K
-6.53%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
60.19K
-4.31%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
58.41K
-16.62%

收入明细

FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
Sales of generic pharmaceutical products
90.30M
0.00%
Sales of rare disease pharmaceutical products
81.65M
0.00%
Sales of Cortrophin Gel
81.65M
0.00%
Sales of branded pharmaceutical products
17.11M
0.00%
由于公司未披露,未能获取相关数据
业务
地区
业务USD
名称
营收
占比
Sales of generic pharmaceutical products
90.30M
0.00%
Sales of rare disease pharmaceutical products
81.65M
0.00%
Sales of Cortrophin Gel
81.65M
0.00%
Sales of branded pharmaceutical products
17.11M
0.00%

股东统计

更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
10.43%
The Vanguard Group, Inc.
5.67%
Meridian Venture Partners
4.52%
State Street Investment Management (US)
3.17%
Esjay L.L.C,
2.82%
其他
73.39%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
10.43%
The Vanguard Group, Inc.
5.67%
Meridian Venture Partners
4.52%
State Street Investment Management (US)
3.17%
Esjay L.L.C,
2.82%
其他
73.39%
股东类型
持股股东
占比
Investment Advisor
41.11%
Investment Advisor/Hedge Fund
23.24%
Hedge Fund
19.41%
Individual Investor
7.45%
Research Firm
6.42%
Private Equity
4.52%
Corporation
2.84%
Pension Fund
1.67%
Bank and Trust
1.33%

机构持股

更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
507
21.97M
100.49%
+14.84K
2025Q3
525
21.96M
103.27%
+407.79K
2025Q2
506
21.46M
110.44%
-446.10K
2025Q1
489
21.61M
106.49%
-1.37M
2024Q4
469
21.12M
108.93%
+156.97K
2024Q3
453
20.75M
88.54%
+3.60M
2024Q2
425
17.36M
85.19%
+1.07M
2024Q1
403
16.22M
82.13%
-1.01M
2023Q4
390
16.10M
82.95%
+39.70K
2023Q3
378
15.97M
79.12%
+734.26K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
2.37M
10.64%
-68.37K
-2.80%
Jun 30, 2025
The Vanguard Group, Inc.
1.27M
5.71%
+95.32K
+8.09%
Jun 30, 2025
Meridian Venture Partners
1.01M
4.55%
-150.00K
-12.88%
Aug 21, 2025
State Street Investment Management (US)
716.12K
3.21%
+1.55K
+0.22%
Jun 30, 2025
Esjay L.L.C,
632.62K
2.84%
-200.00K
-24.02%
Mar 14, 2025
Global Alpha Capital Management Ltd.
862.09K
3.87%
+126.50K
+17.20%
Jun 30, 2025
UBS Financial Services, Inc.
401.55K
1.8%
+137.16K
+51.88%
Jun 30, 2025
Citadel Advisors LLC
569.63K
2.56%
-153.70K
-21.25%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
553.89K
2.48%
-77.67K
-12.30%
Jun 30, 2025
Geode Capital Management, L.L.C.
427.55K
1.92%
-2.08K
-0.48%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Invesco Pharmaceuticals ETF
2.63%
State Street SPDR S&P Pharmaceuticals ETF
2.42%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.95%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.63%
Innovator IBD Breakout Opportunities ETF
1.38%
Innovator IBD 50 Fund ETF
1.02%
Invesco Dorsey Wright Healthcare Momentum ETF
0.98%
Invesco S&P SmallCap Health Care ETF
0.96%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.92%
First Trust Small Cap Growth AlphaDEX Fund
0.67%
查看更多
Invesco Pharmaceuticals ETF
占比2.63%
State Street SPDR S&P Pharmaceuticals ETF
占比2.42%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比1.95%
Pacer US Small Cap Cash Cows Growth Leaders ETF
占比1.63%
Innovator IBD Breakout Opportunities ETF
占比1.38%
Innovator IBD 50 Fund ETF
占比1.02%
Invesco Dorsey Wright Healthcare Momentum ETF
占比0.98%
Invesco S&P SmallCap Health Care ETF
占比0.96%
Janus Henderson Small/Mid Cap Growth Alpha ETF
占比0.92%
First Trust Small Cap Growth AlphaDEX Fund
占比0.67%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

ANI Pharmaceuticals Inc的前五大股东是谁?

ANI Pharmaceuticals Inc 的前五大股东如下:
BlackRock Institutional Trust Company, N.A.持有股份:2.37M,占总股份比例:10.64%。
The Vanguard Group, Inc.持有股份:1.27M,占总股份比例:5.71%。
Meridian Venture Partners持有股份:1.01M,占总股份比例:4.55%。
State Street Investment Management (US)持有股份:716.12K,占总股份比例:3.21%。
Esjay L.L.C,持有股份:632.62K,占总股份比例:2.84%。

ANI Pharmaceuticals Inc的前三大股东类型是什么?

ANI Pharmaceuticals Inc 的前三大股东类型分别是:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Meridian Venture Partners

有多少机构持有ANI Pharmaceuticals Inc(ANIP)的股份?

截至2025Q4,共有507家机构持有ANI Pharmaceuticals Inc的股份,合计持有的股份价值约为21.97M,占公司总股份的100.49%。与2025Q3相比,机构持股有所增加,增幅为-2.78%。

哪个业务部门对ANI Pharmaceuticals Inc的收入贡献最大?

在FY2025Q2,Sales of generic pharmaceutical products业务部门对ANI Pharmaceuticals Inc的收入贡献最大,创收90.30M,占总收入的--%。
KeyAI